Mechanism of action of decitabine in treating acute lymphoblastic leukemia. [PDF]
Gao X +8 more
europepmc +1 more source
Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia [PDF]
core +1 more source
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes. [PDF]
Wei Y +12 more
europepmc +1 more source
Effective Non-Invasive Delivery of Epigenetic Drugs Using Functionalized Accessory Unit Conjugates. [PDF]
Tashima T.
europepmc +1 more source
Rewriting nuclear epigenetic scripts in mitochondrial diseases as a strategy for heteroplasmy control. [PDF]
Pérez MJ +6 more
europepmc +1 more source
Hypermethylation of microRNA-34c CpG Island predicts unfavorable prognosis in acute myeloid leukemia. [PDF]
Yang D, Yan M, Guo J, Wu L.
europepmc +1 more source
Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy. [PDF]
Tang J +7 more
europepmc +1 more source
Correction to "Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine". [PDF]
europepmc +1 more source
Effective treatment of peritoneal myeloid sarcoma with decitabine and venetoclax: A case report. [PDF]
Sudireddy K +8 more
europepmc +1 more source
Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia. [PDF]
Rockwell B +20 more
europepmc +1 more source

